Korea University · Medicine
Professor Eun Joo Kang's research lab focuses on translational oncology, with a primary emphasis on understanding the biological behavior and clinical outcomes of aggressive cancers, particularly in the context of metastasis and patient-specific risk factors. The lab investigates the prognostic implications of specific biomarkers—such as ALDH1 in breast cancer and PD-L1 expression in NSCLC—while also exploring the impact of comorbid conditions like COPD on treatment outcomes in metastatic lung cancer. A significant portion of the research is grounded in real-world population data, utilizing national health insurance claims to identify pregnancy-related risk factors in postpartum breast cancer. The lab’s work bridges clinical oncology, molecular pathology, and health services research to improve patient stratification and personalized treatment strategies.
Figures are computed from collected data and may differ slightly.
In this first randomized trial in patients with ACC, axitinib significantly increased the 6-month PFS rate as compared with observation. (ClinicalTrials.gov number, NCT02859012).
Our study demonstrates the poor prognosis of SCLC patients with bone metastases. Physicians should treat SCLC patients with bone metastases with caution.
ALDH1, biologically aggressive, breast cancer.
Patients with postpartum breast cancer have been reported to have a poor prognosis. The present study aimed to evaluate the pregnancy-related risk factors of postpartum breast cancer in Korea. We collected patient data from the Korea National Health Insurance (KNHI) Claims Database of the Health Insurance Review and Assessment Service (HIRA) for the 2009-2013 period. We evaluated the pregnancy-related risk factors for postpartum breast cancer in two population groups. For Group 1 (women who had
Initial brain metastases are common in NSCLC patients with positive PD-L1 expression. Further studies are necessary to understand the relationship between early brain metastasis and cancer immunity.
Careful attention is required when chemotherapeutic agents are administered to patients with metastatic NSCLC with accompanying COPD with a FEV1 value of less than 80% predicted.
Visceral larva migrans (VLM) syndrome is a clinical manifestation of systemic organ involvement by Toxocara species. VLM with involvement of the bladder and liver is a rare finding. A 62-year-old woman presented with diffuse bladder wall thickening and multiple liver masses with peripheral eosinophilia and urinary symptoms. We considered malignancy or eosinophilic cystitis through clinical manifestations and imaging findings. However, no suspicious malignant lesions were observed on cystoscopy a
Our data showed that the efficacy of various platinum doublet regimens was similar in patients with wild-type EGFR nonsquamous NSCLC.
CT2 should be considered for patients with advanced BTC, especially for those who have only 1 metastatic organ and remain in generally good medical condition after the failure of CT1.
HNCA survivors with hypertension, DM, and hyperlipidemia should be cautious of the risks of CVD and stroke.
The combination regimen of mitomycin-C/5-FU/leucovorin showed marginal activity and tolerable toxicity profiles in heavily pretreated metastatic colorectal cancer patients.
Missing teeth were the most important dental indicator associated with cancer risk. Korean adults with missing teeth should be cautious about the risk of several cancers, particularly head and neck, lung, gastrointestinal, hepatobiliary, and pancreatic cancer.
Tepotinib demonstrated consistent antitumor activity in patients with METex14, and promising antitumor activity in various cancers with MET amplification. Detection of MET dysregulation by plasma NGS may predict the response to tepotinib.
Open papers in the app to read, cite, and organize with AI.
